Alignment Healthcare, Inc. operates a consumer-centric healthcare platform for seniors in the United States. Through its Medicare Advantage plans, it provides a customized healthcare experience designed to meet seniors' needs. The company was founded in 2013 and is based in Orange, California.
ALHC hit by whistleblower probe, star downgrade; guidance raised
▼
Whistleblower accounting probe A former executive's whistleblower complaint alleges accounting irregularities and misclassified expenses, prompting a securities law investigation. The stock fell 16.7% on the news. If true, it could force financial restatements and erode investor trust, weighing on the shares.
This is a new, serious regulatory and credibility risk that directly pressures ALHC's stock.
▲
Raised 2026 outlook on strong first half Alignment raised full-year 2026 guidance after membership jumped 31.5% and first-half adjusted EBITDA rose 60%. But management plans heavy second-half spending, so third-quarter EBITDA is projected at just $20–30 million versus $68.1 million in Q2. The growth is real but near-term profit will dip.
It shows the underlying business is growing and management is confident, a positive counterweight to the bad news.
Medicare Advantage prior authorization bill A bipartisan bill would force MA plans to honor prior authorizations and ban retroactive payment clawbacks. If passed, it would raise medical loss ratios and compliance costs for insurers like Alignment. The stock fell 12.6% on the news.
This is a new regulatory threat that could squeeze ALHC's margins and profitability.
Medicare star rating downgrade CMS downgraded Alignment's largest California contract to 3.5 stars from 4, covering about 81% of its members. That cuts quality bonus payments starting in 2028, hitting future revenue. The stock fell over 20% on the day, a major blow to earnings outlook.
This is the most severe new negative event, directly reducing future federal funding and investor confidence.
BofA Downgrades Alignment Healthcare After CMS Cuts Star Rating on Key California MA Contract
BofA Securities downgraded Alignment Healthcare to Neutral from Buy on Friday after CMS lowered its Star Rating for one of its major California Medicare Advantage contracts to 3.5 stars from 4. The bank cut its price target to $9 from $25, roughly 19% upside based on the Oct. 9 close. BofA noted that Alignment Healthcare went from having all of its members in plans with at least 4 stars to just 25%, with the important California contract H3815 responsible for 75% of the managed care company's MA membership. Because contracts rated below 4 stars are not eligible for bonus payments from CMS, analyst Kevin Fischbeck said this potentially makes it more difficult to expand profitably into new markets, though he added there is a potential silver lining: if the company can move up its star rating on that one contract, there will be a meaningful lift to profitability in 2029. Alignment Healthcare closed down about 13%.
ALHC · Regulation · Negative CMS lowered the Star Rating on its key California MA contract to 3.5 stars, cutting bonus eligibility and prompting BofA's downgrade and PT cut to $9.
BAC · Capital · Neutral BofA Securities is the bank issuing the downgrade and price-target cut on Alignment Healthcare, not a subject of the news.
Alignment Healthcare Expands to 25 California Counties as Key HMO Contract Downgraded to 3.5 Stars
Alignment Health Plan said it will expand into Kern, Kings and Tulare counties and add Hoag and Astrana Health to its California Medicare Advantage provider network from 2027, widening its reach to 25 counties covering more than 6.3 million Medicare beneficiaries. At the same time, the company's largest California HMO contract was downgraded to 3.5 stars in the 2027 Medicare Star Ratings, raising questions about future quality bonus payments. Alignment is disputing the 3.5 star rating on its main California HMO contract through an appeal and legal challenge. The company's narrative projects $9.1 billion in revenue and $200.0 million in earnings by 2029, requiring 25.9% yearly revenue growth and a $159.3 million earnings increase from $40.7 million today. Before the news, the most optimistic analysts assumed revenue growth of about 27.6% a year and earnings of roughly US$247.9 million by 2029, a view that depends heavily on sustained quality metrics the new rating calls into question.
ALHC · Demand · Positive Expanding into Kern, Kings and Tulare counties and adding providers, widening reach to 25 counties covering 6.3 million Medicare beneficiaries.
ALHC · Regulation · Neutral Largest California HMO contract downgraded to 3.5 stars in 2027 Medicare Star Ratings, threatening quality bonus payments, though Alignment is appealing and expanding to 25 counties.
ASTH · Demand · Positive Astrana Health added to Alignment's California Medicare Advantage provider network from 2027, expanding its patient reach.
Hoag Hospital · Demand · Positive Hoag added to Alignment's California Medicare Advantage provider network from 2027, expanding its patient reach.
Humana Jumps 13% on Medicare Star Upgrade; Delta Falls on Q3 Miss
Humana shares surged 13% after the Centers for Medicare & Medicaid Services upgraded its primary Medicare Advantage contract, designated H5216, to four stars for 2027, restoring eligibility for quality bonus payments across roughly 2.4 million members. Kopin rose 4% on an $18.6 million sole-source U.S. Army contract for MicroLED microdisplay work, bringing total program funding to $34 million. SpaceX gained 2% after an $8 billion cash deal with Grain Management for up to 14 MHz of nationwide 800 MHz low-band spectrum, a move that sent T-Mobile US, Verizon Communications and AT&T each down more than 6%. On the losing side, Alignment Healthcare tumbled 18% after its primary California contract fell to 3.5 stars, while Delta Air Lines fell 2% on September-quarter adjusted EPS of $1.72 versus the $1.82 consensus and a lowered full-year outlook, with adjusted fuel expense up 62% to $4.14 billion. Apple slipped 2% after Nikkei Asia reported it cut October component orders for the iPhone 18 Pro and iPhone 18 Pro Max by 15% to 20%.
AAPL · Demand · Negative Apple cut October component orders for iPhone 18 Pro/Pro Max by 15-20%, signaling weaker product demand.
ALHC · Regulation · Negative Its primary California Medicare contract fell to 3.5 stars, losing quality bonus eligibility.
DAL · Capital · Negative Delta missed Q3 EPS consensus ($1.72 vs $1.82) and lowered its full-year outlook.
HUM · Regulation · Positive CMS upgraded Humana's primary Medicare Advantage contract H5216 to four stars for 2027, restoring bonus payments.
KOPN · Demand · Positive Kopin won an $18.6M sole-source U.S. Army contract for MicroLED microdisplay work.
SPCX · Capital · Positive SpaceX gained 2% after an $8 billion cash deal with Grain Management for up to 14 MHz of nationwide 800 MHz low-band spectrum.
Delta Cuts Full-Year Outlook as SpaceX Spectrum Deal Rattles Telecoms
Delta Air Lines reported weaker-than-expected third-quarter results and cut its full-year earnings outlook, sending its shares down 4% premarket. The airline earned an adjusted $1.72 per share on revenue of $17.59 billion, below the $1.75 per share and $17.67 billion analysts polled by LSEG had expected, with the company citing higher fuel costs. SpaceX shares rose 4% after Grain Management announced an agreement to sell its nationwide 800 megahertz spectrum portfolio to SpaceX, a move expected to bolster Starlink Mobile's capabilities. The spectrum announcement sent telecom providers lower, with T-Mobile down 7%, AT&T nearly 6% lower and Verizon off more than 5%, while tower stocks American Tower and Crown Castle gained 6% and almost 8% respectively. Humana surged 14% after its largest Medicare Advantage contract saw its rating improve under the Centers for Medicare & Medicaid Services' 2027 Star Ratings, while Alignment Healthcare cratered 23%. Apple fell more than 2% after Nikkei Asia reported the company was cutting component orders for its iPhone 18 Pro, with October production orders for that device and the iPhone 18 Pro Max cut by 15% from original plans.
DAL · Capital · Negative Delta reported weaker-than-expected Q3 results and cut its full-year earnings outlook, citing higher fuel costs.
HUM · Regulation · Positive Humana surged 14% after its largest Medicare Advantage contract's rating improved under CMS' 2027 Star Ratings.
AAPL · Demand · Negative Nikkei Asia reports Apple cut iPhone 18 Pro component orders, with October production orders down 15% from original plans.
ALHC · Regulation · Negative Alignment Healthcare cratered 23% after its largest Medicare Advantage contract's Star Rating was not improved under CMS' 2027 ratings.
SPCX · Capital · Positive SpaceX shares rose 4% after Grain Management agreed to sell its nationwide 800 MHz spectrum portfolio to SpaceX, bolstering Starlink Mobile.
T · Competition · Negative AT&T fell nearly 6% as SpaceX's spectrum deal is expected to strengthen Starlink Mobile's competitive position.
Humana Jumps 16.5%, Alignment Healthcare Falls Over 20% on Medicare Star Rating Reversals
Humana's largest Medicare Advantage contract recovered to 4 stars from 3.5 stars in the 2027 ratings published by the Centers for Medicare & Medicaid Services on October 8, sending its shares up 16.5% on Thursday while rival Alignment Healthcare tumbled more than 20% after its largest California contract was downgraded to 3.5 stars from 4. The improvement restores Humana's eligibility for federal quality bonus payments, potentially providing a significant boost to the insurer's earnings in 2028. Alignment's downgraded contract accounted for approximately 81% of the company's membership as of September 2025. The developments mark a reversal of fortunes for the two insurers: Humana suffered a major ratings collapse in 2024, when the proportion of members enrolled in plans rated at least 4 stars plunged from 94% to 25% for the following year, while Alignment had emerged as an industry outperformer with 100% of its membership in plans rated at least 4 stars for 2026. CMS assigns Medicare Advantage plans ratings ranging from 1 to 5 stars based on measures including clinical outcomes, customer experience and plan performance, and contracts achieving at least 4 stars qualify for quality bonus payments that increase federal funding available to insurers; the newly published ratings will primarily affect payments and company revenues in 2028.
ALHC · Regulation · Negative CMS downgraded Alignment's largest California contract to 3.5 stars from 4, covering ~81% of membership, cutting quality bonus payments.
HUM · Regulation · Positive CMS restored Humana's largest Medicare Advantage contract to 4 stars, regaining eligibility for federal quality bonus payments.
Alignment Healthcare Earns 4 Stars or Higher on Six of Seven Rated Medicare Advantage Contracts
Alignment Healthcare, Inc. announced that six of its seven Medicare Advantage contracts eligible for rating earned 4 Stars or higher in the Centers for Medicare & Medicaid Services' 2027 Star Ratings, including three plans that achieved an overall 4.5-Star Rating. The high-performing contracts span Arizona, California, Nevada, North Carolina and Texas. The company also reported that its California H3815 HMO contract received a 3.5-Star Rating for 2027, a result Alignment says does not accurately reflect the contract's longstanding performance on evidence-based measures of quality, clinical outcomes and member experience. Dawn Maroney, president of Alignment Health and CEO of Alignment Health Plan, said the current Star Ratings framework has drifted too far from accurate quality measurement, and that the company intends to pursue all available administrative remedies and to litigate the measures and methodologies it believes warrant review. Maroney added that Alignment remains confident in its ability to return the California HMO contract to at least a 4-Star Rating. The 2027 Star Ratings were published by CMS on Oct. 8, 2026, with plan enrollment as of September 2026.
Humana Shrinks Medicare Advantage Footprint for 2027
Humana will offer Medicare Advantage plans in nearly 2,600 counties across 45 states and Washington, D.C. for the 2027 plan year, a sharp reduction from the 46 states and Washington, D.C. it covered for 2026, when its plans reached 85% of U.S. counties. The Louisville, Kentucky-based insurer, the second-largest MA player behind UnitedHealth, said the new footprint represents more than 80% of U.S. counties, and it has announced plans to discontinue offerings affecting 600,000 enrollees. UnitedHealth said its UnitedHealthcare MA plans will remain accessible to 94% of Medicare-eligible individuals next year, unchanged from 2026, though Bloomberg reported that roughly 390,000 people will be part of plans being shut down. CVS Health's Aetna unit and Centene are also pulling back their MA offerings, according to CMS data reviewed by Wall Street analysts, while Alignment Healthcare is expanding to 55 counties and Clover Health said its plans will reach 5.2M Medicare-eligible individuals across 203 counties in five states. The moves come as the MA market contends with rising medical costs and intense government scrutiny, and after CMS said 2027 MA enrollment is expected to reach 34M, a 6% decline, despite a more than 16% drop in MA premiums versus 2026 on a weighted average basis.
HUM · Regulation · Negative Humana is sharply shrinking its 2027 Medicare Advantage footprint and discontinuing plans affecting 600,000 enrollees amid rising costs and government scrutiny.
ALHC · Demand · Positive Alignment Healthcare is expanding its Medicare Advantage footprint to 55 counties, a growth move against peers' pullbacks.
CLOV · Demand · Positive Clover Health said its plans will reach 5.2M Medicare-eligible individuals across 203 counties in five states, an expansion.
CNC · Regulation · Negative Centene is pulling back its Medicare Advantage offerings amid rising medical costs and intense government scrutiny.
CVS · Regulation · Negative CVS Health's Aetna unit is pulling back its Medicare Advantage offerings amid rising medical costs and government scrutiny.
UNH · Regulation · Neutral UnitedHealth's MA plans stay at 94% coverage unchanged, but ~390,000 enrollees are in plans being shut down amid MA market scrutiny and rising costs.
Medicare Advantage Prior Authorization Bill Sinks Insurer Stocks
Bipartisan lawmakers introduced the Protecting Approved Care Act, legislation aimed at reforming prior authorization and payment rules in Medicare Advantage plans, sending several health insurer stocks lower in the morning session. The bill, which received key backing from the American Association of Orthopaedic Surgeons, would require Medicare Advantage health plans to honor initial prior authorizations and strictly prohibit retroactive payment clawbacks. If enacted, the legislation would curtail insurers' ability to adjust or deny reimbursements post-treatment, potentially increasing medical loss ratios and raising administrative compliance burdens across managed care organizations. Among the stocks impacted, Alignment Healthcare fell 12.6%, Clover Health fell 4.8%, Novavax fell 3.6%, and Astrana Health fell 2.7%. Alignment Healthcare's shares are very volatile and have had 23 moves greater than 5% over the last year, and the stock is down 49% since the beginning of the year, trading at $10.32 per share, 58% below its 52-week high of $24.56 from July 2026.
ALHC · Regulation · Negative The Protecting Approved Care Act would bar retroactive clawbacks and force honoring of prior authorizations, raising medical loss ratios for Alignment Healthcare.
ASTH · Regulation · Negative Astrana Health fell as the Medicare Advantage prior-authorization reform bill threatens insurer reimbursement flexibility and raises compliance burdens.
CLOV · Regulation · Negative Clover Health dropped on the bill curtailing Medicare Advantage plans' ability to deny or claw back reimbursements post-treatment.
Brent tops $100, Treasury yields climb as U.S. equities slip
U.S. equities pushed lower on Wednesday as oil kept climbing, with Brent crude breaking above $100 a barrel while U.S.–Iran tensions in the Middle East continued to weigh on sentiment. Treasury yields advanced after the Treasury Department said it will repurchase up to $6 billion of longer-dated notes in Thursday's operation, tripling the size of its last long-end buyback; the 2-year yield rose 2 basis points to 4.42%, the 10-year added 5 basis points to 4.84%, and the 30-year gained about 4 basis points near 5.29%. Brent crude futures surged above $100 per barrel for the first time since July 24, with front-month Brent for November delivery climbing 3.3% to $101.13/bbl and Nymex crude jumping 3.2% to $96.02/bbl, as traffic through the Strait of Hormuz dropped from roughly 8 million barrels per day in late August to only 1 million barrels per day this week, according to Rystad Energy. Separately, Anthropic's Alignment Science Lead Evan Hubinger said he "earnestly" believes AI could kill all humans, putting his personal estimate of the probability at more than 10% within the next decade, and the company's latest risk report upgraded the risk from misalignment in high-stakes settings to "low" from "very low." Managed care stocks declined after CVS Health said at the Wells Fargo Healthcare Conference that it continues to face elevated medical costs, with notable decliners including UnitedHealth, Humana, Clover Health, Alignment Healthcare, Centene, Oscar Health, Elevance Health, and Molina Healthcare.
Alignment Healthcare moves to dismiss whistleblower lawsuit
Alignment Healthcare has filed a motion to dismiss a whistleblower lawsuit in which a former company executive accused the Medicare-driven health insurer of manipulating its finances to boost its stock price. Shares of the Orange, California-based firm plunged in early July after media reports indicated that ex-employee Hakan Kardes filed the case in a federal court in Santa Ana. Citing a court filing, Bloomberg reported that the company has dismissed the allegations as a case of sour grapes. Alignment said in a statement that a third-party investigation found Kardes' Sarbanes-Oxley whistleblower claims are false and there is no basis for his allegations. The company cited multiple reasons for the dismissal, including that the plaintiff filed whistleblower claims too late, and added that Kardes sued only after realizing that an in-house restructuring initiative didn't roll out as he expected.
Alignment Healthcare Raises 2026 Outlook After Strong First Half
Alignment Healthcare raised its full-year 2026 guidance following a second quarter that saw membership jump 31.5% to about 294,100 and adjusted EBITDA climb 60% year over year to $106 million for the first half. The company now expects 2026 revenues of $5.195 billion to $5.225 billion, membership of 298,000 to 301,000, adjusted gross profit of $630 million to $650 million, and adjusted EBITDA of $145 million to $163 million. However, management plans heavier clinical, artificial intelligence, and expansion spending in the second half, with third-quarter adjusted EBITDA projected at just $20 million to $30 million compared with $68.1 million in the second quarter. The company’s adjusted medical benefit ratio improved 40 basis points year over year to 86.3%, its lowest since going public, while adjusted selling, general and administrative expenses fell to 8.7% of revenues. The stock carries a Zacks Rank #3 (Hold).
Alignment Healthcare reported second-quarter 2026 membership growth of 31.5% to about 294,100 and revenue growth of 31.6% to $1.34 billion, while raising its full-year outlook to 298,000–301,000 members and revenues of $5.20–$5.23 billion. Adjusted gross profit rose 35.3% to $182.9 million, the adjusted medical benefit ratio improved 40 basis points to 86.3%, and adjusted EBITDA climbed 48.4% to $68.1 million. Despite the operating momentum, the stock trades at a forward price-to-earnings ratio of 68.4 and an enterprise value-to-EBITDA ratio of 53.0, and management guided for third-quarter adjusted EBITDA of only $20–$30 million due to higher-acuity new members and seasonal spending. With a $14 price target only modestly above the recent $13.68 close, Zacks Investment Research rates the stock a Hold, citing limited near-term upside and second-half execution risk.
Kaplan Fox investigates Alignment Healthcare for possible securities law violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. The investigation follows a July 8, 2026 whistleblower complaint by a former executive alleging accounting irregularities that artificially inflated previously reported and projected financial results, including Adjusted EBITDA, and that millions of dollars in operating expenses were systematically misclassified as capital expenditures. On that day, Alignment Healthcare stock fell $4.02 per share, or 16.7%, to close at $20.03 per share. Kaplan Fox is a nationally recognized plaintiffs' securities litigation firm that has recovered more than $10 billion for clients and classes.
Glancy Prongay Wolke & Rotter LLP continues its investigation into Alignment Healthcare, Inc. for possible violations of federal securities laws following a 16% stock price drop on July 8, 2026. A former chief transformation officer filed a whistleblower lawsuit alleging the company deliberately misclassified $8 million to $10 million in routine operating expenses as capital expenditures to artificially inflate adjusted EBITDA and report its first full year of positive adjusted EBITDA as a public company. On the news, Alignment’s stock fell $4.02, or 16.7%, to close at $20.03 per share, injuring investors.
The Law Offices of Frank R. Cruz continues its investigation into Alignment Healthcare for possible federal securities law violations after a whistleblower lawsuit alleged the company misclassified up to $10 million in routine operating expenses as capital expenditures to artificially inflate adjusted EBITDA. The former chief transformation officer's suit claims this allowed Alignment to report its first full year of positive adjusted EBITDA as a public company. On July 8, 2026, the stock fell $4.02, or 16.7%, to close at $20.03 per share.
Lowey Dannenberg Investigates Alignment Healthcare for Potential Securities Law Violations
Lowey Dannenberg P.C. is investigating Alignment Healthcare, Inc. for potential violations of federal securities laws. The investigation follows a July 8, 2026 whistleblower lawsuit filed by a former executive alleging the company misclassified $8 million to $10 million in routine operating expenses as capital expenditures to artificially inflate adjusted EBITDA. Following the news, Alignment stock fell $4.02 per share, or approximately 16.7%, to close at $20.03 per share. The law firm is examining whether the company and its executives provided accurate and complete information to investors.
ALHC · Capital · Negative Whistleblower lawsuit alleges misclassification of operating expenses as capital expenditures to inflate adjusted EBITDA, leading to a 16.7% stock drop.
Alignment Healthcare Q2 2026 Earnings Call Transcript Released
Alignment Healthcare held its second-quarter 2026 earnings call. The transcript of the call has been released, providing details on the company's financial performance and outlook. No specific financial figures or guidance changes were highlighted in the announcement.
Kaplan Fox Investigates Alignment Healthcare Over Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP announced an investigation into potential securities violations against Alignment Healthcare, Inc. On July 8, 2026, a former executive filed a whistleblower complaint alleging accounting irregularities that artificially inflated previously reported and projected financial results, including Adjusted EBITDA, a key non-GAAP metric tied to executive compensation. The complaint claims millions of dollars in operating expenses were systematically misclassified as capital expenditures. Following the news, Alignment Healthcare shares fell $4.02, or 16.7%, to close at $20.03 per share. Kaplan Fox is a nationally recognized plaintiffs' securities litigation firm with a track record of recovering more than $10 billion for clients.
HBSS Launches Investigation into Alignment Healthcare After Whistleblower Alleges Financial Manipulation
National shareholder rights firm Hagens Berman has launched an investigation into Alignment Healthcare following a whistleblower lawsuit alleging systemic financial manipulation. The lawsuit, filed by former chief transformation officer Hakan Kardes, claims the company misclassified operating expenses as capital expenditures to inflate adjusted EBITDA for 2024 and 2025, boosting key performance metrics tied to stock price and executive compensation. Alignment Healthcare's stock fell approximately 16.7% in a single day after the allegations became public on July 8, 2026, marking its worst single-day performance since February 2024. The decline came shortly after the company had reported strong first-quarter 2026 results and raised full-year guidance, driving shares toward 52-week highs. Hagens Berman is encouraging investors who suffered significant losses to contact the firm.
Holzer & Holzer Investigates Alignment Healthcare Over Alleged Expense Misclassification
Holzer & Holzer, LLC announced an investigation into whether Alignment Healthcare, Inc. complied with federal securities laws. The investigation follows a July 7, 2026 lawsuit by a former executive alleging retaliation after internally reporting that the company materially misclassified millions of dollars in operating expenses as capital expenditures. Alignment Healthcare's stock price dropped following the news. Investors who purchased Alignment stock and suffered a loss are encouraged to contact the law firm.
Bragar Eagel & Squire, P.C. is investigating Alignment Healthcare, Inc. on behalf of stockholders over potential securities law violations. The investigation follows a July 8, 2026 Modern Healthcare report that a former executive filed a whistleblower lawsuit alleging the company misclassified routine operating expenses as capital expenditures to artificially inflate adjusted EBITDA and report its first full year of positive adjusted EBITDA as a public company. Alignment's stock fell $4.02, or 16.7%, to close at $20.03 per share on July 8, 2026 after the news. The law firm encourages investors who suffered losses to contact partners Brandon Walker or Melissa Fortunato to discuss their legal rights.
Kaplan Fox Investigates Alignment Healthcare for Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP announced an investigation into Alignment Healthcare, Inc. for potential securities law violations. The investigation follows a July 8, 2026 whistleblower complaint by a former executive alleging accounting irregularities that artificially inflated previously reported and projected financial results, including Adjusted EBITDA, a key non-GAAP metric tied to executive compensation. The complaint claims millions of dollars in operating expenses were systematically misclassified as capital expenditures. On the same day, Alignment Healthcare stock fell $4.02 per share, or 16.7%, to close at $20.03 per share.
Alignment Healthcare plunges on whistleblower lawsuit report
Shares of Alignment Healthcare fell as much as 19% on Wednesday after Modern Healthcare reported the company is facing a whistleblower lawsuit. The publication said a former executive at the California-based company claims Alignment manipulated its finances to increase its stock price, citing the lawsuit filed Tuesday. A spokesperson for Alignment told Bloomberg the company believes these allegations are wholly without merit and that it intends to vigorously defend itself. The spokesperson said Hakan Kardes voluntarily resigned from the company in April 2025.
HBSS Launches Investigation into Alignment Healthcare Following Whistleblower Allegations of Financial Manipulation
National shareholder rights firm Hagens Berman has launched an investigation into Alignment Healthcare following a whistleblower lawsuit alleging systemic financial manipulation. The lawsuit, filed by former chief transformation officer Hakan Kardes, claims the company misclassified operating expenses as capital expenditures to inflate adjusted EBITDA for 2024 and 2025, boosting key performance metrics tied to stock price and executive compensation. Following the disclosure, Alignment Healthcare's stock fell approximately 16.7% in a single day, its worst performance since February 2024. The firm is investigating whether Alignment misled investors about its financial health and internal controls.
Block & Leviton Investigating Alignment Healthcare for Possible Securities Fraud
Block & Leviton is investigating Alignment Healthcare for potential securities law violations. On July 8, 2026, a former executive filed a whistleblower lawsuit alleging the company manipulated its finances to boost its stock price and executive compensation. The allegations follow Alignment Healthcare's report of strong first-quarter 2026 results, including sharply higher revenue, a swing to profitability, rising adjusted EBITDA, and a jump in operating cash flow, which led the company to raise its full-year guidance. After the whistleblower lawsuit was reported, Alignment Healthcare's stock price fell approximately 16.72% in a single day. Investors who purchased Alignment Healthcare securities and suffered losses may be eligible for compensation.
Alignment Healthcare Shares Jump 10.7% After Earnings Beat, Membership Growth, and Higher Star Ratings
Alignment Healthcare shares rose 10.7% after the company reported quarterly revenues of US$1.24 billion, a 33.3% year-on-year increase, with earnings per share exceeding expectations and membership expanding by 48,500 to 284,800. Analysts sharply raised full-year earnings estimates, and the company secured higher Star Ratings across all member plans for the 2026 payment year, which directly influence reimbursement and could support revenue per member. Despite softer near-term EBITDA guidance, the combination of robust revenue growth, membership gains, and improved quality ratings strengthens the near-term earnings catalyst, though core policy and competition risks remain.
Alignment Healthcare Stock Trades at 45% Discount to DCF Estimate
Alignment Healthcare shares appear undervalued, with a Discounted Cash Flow model estimating intrinsic value at about $43.72 per share compared to the current price of $24.01, implying a roughly 45.1% discount. The stock has returned about 321.2% over three years, yet the DCF analysis, based on trailing free cash flow of approximately $204.1 million, suggests the market is pricing the senior-focused health insurer below its projected cash generation. Additionally, Alignment Healthcare trades on a price-to-sales ratio of about 1.2 times, below the healthcare industry average of around 1.5 times and a peer group average of about 2.3 times, while screening as undervalued in five of six valuation tests. The key question remains whether the company can scale its membership and control medical costs without reimbursement or execution setbacks that could challenge the apparent discount.
StockStory highlights Five Below, Alignment Healthcare, and CNX Resources as growth stocks with explosive upside
StockStory identified Five Below, Alignment Healthcare, and CNX Resources as three growth stocks with strong competitive advantages and explosive upside potential. Five Below, the discount retailer, posted 25.9% annual revenue growth and averaged 8% same-store sales growth over two years, with expected revenue growth of 10% in the next 12 months. Alignment Healthcare, a Medicare Advantage provider, achieved 41.8% annual revenue growth and 45.4% over two years, while its earnings per share grew 28.5% annually over four years and free cash flow margin expanded by 11 percentage points over five years. CNX Resources, a natural gas producer, reported 15% revenue growth, a 68% gross margin, and a 23.4% free cash flow margin, with EBITDA profits rising over five years due to improved efficiency.
ALHC · Demand · Positive Alignment Healthcare is highlighted as a growth stock with strong revenue growth and expanding margins, indicating strong demand for its Medicare Advantage plans.
CNX · Capital · Positive CNX Resources is highlighted as a growth stock with strong financial metrics (revenue growth, high margins, rising EBITDA), implying positive valuation outlook.
FIVE · Demand · Positive Five Below is highlighted as a growth stock with strong revenue and same-store sales growth, indicating robust customer demand.
Health Insurance Providers Stocks Q1 In Review: Alignment Healthcare Vs Peers
Alignment Healthcare reported first-quarter revenues of $1.24 billion, up 33.3% year on year, exceeding analysts' expectations by 1.3%. The company added 48,500 customers to reach a total of 284,800, but its EBITDA guidance for the next quarter missed analysts' expectations, making it the weakest guidance update among the 12 health insurance providers stocks tracked. CVS Health posted the biggest analyst estimate beat with revenues of $100.4 billion, up 6.2% year on year, while Cencora had the weakest quarter with revenues of $78.36 billion, falling short of expectations by 3.9%. Oscar Health reported revenues of $4.65 billion, up 52.6% year on year, but lagged analysts' expectations by 5.7%, and Progyny reported revenues of $328.5 million, up 1.4% year on year, surpassing expectations by 0.7% and achieving the highest guidance raise among its peers. Overall, the group's revenues beat consensus estimates by 1.4%, and share prices have risen 36.3% on average since the latest earnings results.
StockStory Picks Alignment Healthcare as a Long-Term Buy, Flags Akamai and Sinclair as Sells
StockStory highlights Alignment Healthcare as a Wall Street favorite with strong fundamentals, while warning investors to avoid Akamai Technologies and Sinclair despite consensus price targets implying returns above 20%. Alignment Healthcare, a Medicare Advantage provider, posted 45.4% annual revenue growth over two years and a free cash flow margin that jumped 11 percentage points over five years. Akamai faces underwhelming billings growth of 6.8%, a gross margin of 58.3% that trails competitors, and an expected 25.3 percentage point drop in free cash flow margin. Sinclair has seen sales decline 11.4% annually over five years and carries a 7× net-debt-to-EBITDA ratio that may force dilutive equity offerings.
AKAM · Capital · Negative StockStory flags Akamai as a sell due to underwhelming billings growth, low gross margin, and expected free cash flow margin drop.
ALHC · Capital · Positive StockStory highlights Alignment Healthcare as a long-term buy with strong revenue growth and improving free cash flow margin.
SBGI · Capital · Negative StockStory warns against Sinclair due to declining sales and high leverage that may force dilutive equity offerings.
Zacks Highlights Four Liquid Stocks With Strong Growth Potential
Zacks Investment Research has identified four top-ranked stocks with sound liquidity and strong growth potential that investors may consider to maximize returns. The four stocks are Alignment Healthcare, Argan, Agilysys, and Ciena Corporation. The screening used current, quick, and cash ratios between 1 and 3, asset utilization above the industry average, a Zacks Rank of 1, and a Growth Score of B or better, narrowing a universe of over 7,700 stocks to just 15. Alignment Healthcare reported first-quarter 2026 revenues of $1.24 billion, up 33.3% year over year, with health plan membership rising 30.9% to 284,800. Argan posted first-quarter fiscal 2027 revenues of $291 million, a 50% increase, and ended the quarter with a backlog of $2.8 billion. Agilysys delivered fiscal 2026 revenues of $319.3 million, up 15.9%, and guided fiscal 2027 revenues to $365–$370 million with subscription revenue growth north of 30%. Ciena's fiscal second-quarter 2026 revenues surged 39.5% to $1.57 billion, driven by cloud demand, and it expects third-quarter revenues of $1.625 billion.
CVS Health Leads Health Insurer Q1 Earnings with Strongest Beat
CVS Health posted the strongest first-quarter results among 12 tracked health insurance providers, with revenues of $100.4 billion beating analyst expectations by 6.3%. The group overall exceeded revenue consensus by 1.4%, while next-quarter guidance was in line. Centene also outperformed, reporting $49.94 billion in revenue and topping estimates by 6.2%, while Cencora lagged with $78.36 billion, missing forecasts by 3.9%. Progyny and Alignment Healthcare rounded out the cohort, with Progyny raising full-year guidance the most among peers and Alignment adding 48,500 customers to reach 284,800 total members.
Alignment Healthcare Shows Strong Revenue Growth and Improving Profitability
Alignment Healthcare has demonstrated strong business momentum with revenue growing at a 33.6% compounded annual rate over the past five years, outpacing the average healthcare company. The company's full-year earnings per share turned positive over the last four years, signaling a key inflection point. Free cash flow margin expanded by 11 percentage points over five years, reaching 5.3% on a trailing 12-month basis, reflecting improved capital efficiency. Despite these fundamentals, the stock has underperformed, trading at $19.95 per share with a 2.9% decline over the past six months, compared to the S&P 500's 12.4% gain.
USA